Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Sees Significant Growth in Short Interest

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totaling 37,392 shares, an increase of 232.8% from the April 15th total of 11,234 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 74,697 shares, the short-interest ratio is presently 0.5 days.

Institutional Trading of Nanobiotix

Several institutional investors have recently added to or reduced their stakes in NBTX. Millennium Management LLC acquired a new stake in Nanobiotix in the fourth quarter valued at $390,000. Marshall Wace LLP acquired a new stake in Nanobiotix in the fourth quarter valued at $220,000. Optiver Holding B.V. acquired a new stake in Nanobiotix in the third quarter valued at $101,000. Finally, Royal Bank of Canada raised its holdings in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares in the last quarter. 38.81% of the stock is owned by institutional investors and hedge funds.

Nanobiotix Trading Up 5.8%

Shares of NBTX traded up $3.03 during mid-day trading on Thursday, reaching $55.07. 142,428 shares of the stock traded hands, compared to its average volume of 94,216. The stock has a fifty day simple moving average of $34.73 and a 200 day simple moving average of $26.56. Nanobiotix has a 12-month low of $3.60 and a 12-month high of $57.14.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $3.42 million for the quarter. Analysts expect that Nanobiotix will post 0.53 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on NBTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. UBS Group lifted their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Finally, Guggenheim lifted their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $26.67.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.